Mark Lim
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$22.4MFederal grants as PI20 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
20 awards · $22.4M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 2, 2023 | NIH | SBIR Phase II Photocleavable Mass-Tags for Spatial Multiomics of Alzheimer’s Brain Tissue | $1.1M | Ambergen, Inc. |
| Jul 26, 2023 | NIH | SBIR Phase II New Technology for High-Resolution Antibody Profiling for SARS-CoV-2 | $979K | Ambergen, Inc. |
| Jul 24, 2023 | NIH | SBIR Phase II A Highly Multiplexed, Multiomic 3D Mouse Brain Map Using MALDI-IHC | $910K | Ambergen, Inc. |
| Sep 15, 2022 | NIH | SBIR Phase II A Highly Multiplexed, Multiomic 3D Mouse Brain Map Using MALDI-IHC | $1.1M | Ambergen, Inc. |
| Sep 1, 2022 | NIH | SBIR Phase II Photocleavable Mass-Tags for Spatial Multiomics of Alzheimer’s Brain Tissue | $2.4M | Ambergen, Inc. |
| Aug 19, 2022 | NIH | SBIR Phase II New Technology for High-Resolution Antibody Profiling for SARS-CoV-2 | $2.0M | Ambergen, Inc. |
| Jun 16, 2021 | NIH | SBIR Phase II Photocleavage Technology for Blood-based Multi-Biomarker Alzheimer's Disease Assay | $1.2M | Ambergen, Inc. |
| Aug 17, 2020 | NIH | SBIR Phase II Highly Multiplexed Nanoscale Mass Spectrometric Imaging of Cancer Tissues | $1000K | Ambergen, Inc. |
| Aug 1, 2020 | NIH | SBIR Phase II Photocleavage Technology for Blood-based Multi-Biomarker Alzheimer's Disease Assay | $2.5M | Ambergen, Inc. |
| Sep 17, 2019 | NIH | SBIR Phase II Highly Multiplexed Nanoscale Mass Spectrometric Imaging of Cancer Tissues | $1000K | Ambergen, Inc. |
| Nov 29, 2018 | NIH | SBIR Phase II Multiplexed Bead-based In Vitro Pediatric Allergy Test | $1.0M | Ambergen, Inc. |
| Sep 1, 2018 | NIH | SBIR Phase I Highly Multiplexed Nanoscale Mass Spectrometric Imaging of Cancer Tissues | $300K | Ambergen, Inc. |
| Jun 19, 2018 | NIH | SBIR Phase II Mass Spectrometric Bead-Imaging of Off-Target Drug Interactions | $754K | Ambergen, Inc. |
| Jan 9, 2018 | NIH | SBIR Phase II Multiplexed Bead-based In Vitro Pediatric Allergy Test | $1.9M | Ambergen, Inc. |
| Jun 27, 2017 | NIH | SBIR Phase II Mass Spectrometric Bead-Imaging of Off-Target Drug Interactions | $754K | Ambergen, Inc. |
| Sep 1, 2016 | NIH | SBIR Phase II Mass Spectrometric Bead-Imaging of Off-Target Drug Interactions | $754K | Ambergen, Inc. |
| Jul 26, 2016 | NIH | SBIR Phase I Photocleavage Technology for Improved Serum-based Multi-Biomarker Cancer Assays | $225K | Ambergen, Inc. |
| Feb 25, 2016 | NIH | SBIR Phase II Multiplexed Bead-based In Vitro Pediatric Allergy Test | $999K | Ambergen, Inc. |
| Jul 24, 2015 | NIH | SBIR Phase II Global Proteomic Screening by MALDI Spectrometric Imaging of Protein-Bead Arrays | $500K | Ambergen, Inc. |
| Feb 13, 2015 | NIH | SBIR Phase II Multiplexed Bead-based In Vitro Pediatric Allergy Test | $999K | Ambergen, Inc. |
Peer ranks
Federal funding#8
Awards as PI#27
Patents#505
Companies
- Ambergen, Inc.Linked by awards · Medtech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.